International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 03 Issue 08 August 2023

Page No: 1629-1632

DOI: https://doi.org/10.47191/ijmscrs/v3-i8-35, Impact Factor: 6.597

Multidisciplinary Approach and Therapeutic Advances in the Management of Meningioma: A Comprehensive Review

Alejandro Arias Mendoza[1], Ana Laura Esmeralda Muñoz Avendaño[2], Luis Daniel Mendoza Blancas[3], Lisset Guadalupe Hernández Torres[4], Mónica Maya Velasco[5], Alexis Genaro Ortíz Altamirano[5]

[1]Hospital de Especialidades Dr. Bernardo Sepulveda Gutiérrez. Instituto Mexicano del Seguro Social. Centro Médico Nacional Siglo XXI.

[2]Hospital General de Zona 6 Tepeji Del Río – Instituto Mexicano del Seguro Social, México.

[3]Facultad de Medicina, Universidad Nacional Autónoma de México. México

[4]Hospital general de zona 2. Instituto Mexicano del Seguro Social. Aguascalientes, Aguascalientes, México.

[5]Escuela Superior de Medicina, Instituto Politécnico Nacional. México.

ABSTRACT

Meningioma, a predominantly benign intracranial neoplasm originating in the meninges, has been the subject of extensive study in the medical community due to its prevalence, clinical diversity, and associated therapeutic challenges. This article aims to provide a comprehensive review of current advances in the understanding, diagnosis and treatment of meningiomas, focusing on the application of multidisciplinary approaches and innovative therapies.

Through a detailed exploration of the molecular pathogenesis, updated histopathologic classifications, and varied clinical presentations of meningiomas, an in-depth understanding of the inherent heterogeneity of these neoplasms is sought. The importance of advanced neuroimaging, including diffusion-weighted MRI and positron emission tomography, in the accurate assessment of tumor extent and precise surgical planning will be highlighted.

In the therapeutic arena, conventional options, such as surgery and radiation therapy, will be examined in detail and the challenges and limitations associated with these modalities will be discussed. In addition, emerging pharmacologic therapies, such as angiogenesis inhibitors and therapies specifically targeting genetic mutations frequently found in meningiomas, will be reviewed, highlighting their potential to modify the clinical course of the disease.

The multidisciplinary approach, involving close collaboration between neurosurgeons, neuroradiologists, pathologists and oncologists, will be explored in detail, highlighting its crucial role in informed clinical decision making and optimizing patient outcomes. Finally, future prospects and areas of ongoing research, such as immunotherapy and gene therapy, which promise to further revolutionize the therapeutic paradigm for meningiomas, will be outlined.

This article will provide a comprehensive overview of meningiomas, from their molecular basis to state-of-the-art treatment strategies, with the purpose of enriching medical knowledge and fostering a holistic approach in the care of patients affected by this complex pathological entity.

ARTICLE DETAILS

Published On:
15 August 2023

Available on:
https://ijmscr.org/

INTRODUCTION

Meningioma, a primary neoplastic entity of the central nervous system derived from meningeal arachnoid cells, is one of the most common and widely studied intracranial tumors in neuro-oncologic practice. Its origin in the meningeal membranes gives meningioma a unique anatomical feature that places it at the intersection of neuroanatomy and oncologic pathology. This intracranial neoplasm, although mostly benign in nature, presents a clinical and histologic variability that intrigues clinicians, researchers and pathologists alike.

RELEVANCE

Meningioma, an intracranial neoplasm derived from arachnoid meningeal cells, stands as a phenomenon of great

relevance in the spectrum of neuro-oncology due to its significant incidence and its impact on the quality of life of affected patients. The epidemiology of meningiomas has been the subject of thorough analysis, revealing patterns of distribution, prevalence and demographic characteristics that highlight their prominent position in intracranial pathology.

Although meningiomas can occur in any age group, there is a clear trend towards a higher incidence in the adult population, with a peak of diagnoses in the sixth and seventh decade of life. This age pattern suggests a possible relationship with the accumulation of genetic and environmental factors over time, contributing to the development of this neoplastic entity. Women exhibit a particularly high susceptibility, with a female-to-male ratio of diagnoses ranging around 2:1.

In terms of anatomical distribution, meningiomas show a marked predilection for intracranial regions, with a preference for the cerebral hemispheres and the meningeal convexity. However, their location can be extremely diverse, including the cerebral sulci, the cerebellopontine angle and the selar region, among others. This topographic variability accentuates diagnostic and therapeutic complexity, requiring a multidisciplinary approach to address the specific challenges that each location brings.

The clinical relevance of meningiomas lies in their potential to produce a wide range of neurological symptoms, dependent on their location and size. Compressive effects on adjacent brain structures may result in focal neurological deficits, seizures and cognitive impairment. Furthermore, the possibility of progressive tumor growth and recurrence after therapeutic intervention, even in cases of benign histology, adds an additional level of complexity in long-term clinical management.

The epidemiology and relevance of meningioma are manifested in its distinct demographic distribution, its disproportionate incidence in women and its tendency to affect predominantly the adult population. Its variety of clinical presentations and potential for neurologic disability heighten the need for a comprehensive approach to the management of this neoplasm. A thorough understanding of its epidemiology is crucial to guide research and clinical practice in order to improve early diagnosis, effective therapy and quality of life for patients with this disease entity.

CLINIC

Meningioma, an intracranial neoplasm originating in the meninges, is distinguished by its ability to trigger a diverse spectrum of clinical manifestations, depending intrinsically on its anatomical location, size, growth velocity and spatial relationships with surrounding brain structures. This clinical variability enriches the complexity of its presentation and poses significant challenges in terms of diagnosis and therapeutic approach.

The symptomatology derived from a meningioma is intrinsically related to its ability to compress, infiltrate or disrupt the function of adjacent neural tissues and structures. As a result, patients may experience a wide range of neurological symptoms, including motor, sensory and cognitive deficits, as well as alterations in consciousness and balance disorders.

The clinical presentation of meningiomas can be highly heterogeneous and correlates with their specific location. For example, meningiomas located in the cerebral convexity may manifest with headaches, visual disturbances, seizures and motor or sensory disturbances in the opposite hemisphere. Meningiomas in the selar region may cause endocrinological symptoms, such as pituitary dysfunction and hormonal disorders.

Meningiomas that develop in regions close to the cerebellopontine angle may generate auditory and vestibular symptoms, such as unilateral hypoacusis, tinnitus and vertigo. In cases where these tumors exert pressure on the brainstem, symptoms may include facial paralysis, dysphagia, slurred speech and ataxia. Also, compression of the ventricular system can lead to obstructive hydrocephalus, triggering symptoms of increased intracranial pressure, such as severe headache, nausea and vomiting.

The clinical manifestation of meningiomas may also extend beyond the central nervous system, presenting with systemic symptoms by virtue of the release of bioactive molecules by the tumor, such as cytokines and growth factors. These symptoms may include fever of unknown origin, unexplained weight loss and skin manifestations.

The identification and characterization of these symptoms require a multidisciplinary approach, involving neurologists, neuroradiologists, neurosurgeons and oncologists. Neuroimaging plays a key role in determining the location and extent of the meningioma, allowing for accurate surgical and therapeutic planning. The therapeutic choice, which can range from vigilant observation to aggressive surgical resection, depends largely on the clinical and radiological nature of the disease.

In summary, the clinical presentation of meningioma is varied and multifaceted, ultimately depending on its anatomic location and its interaction with surrounding brain tissue. The diversity of neurologic symptoms and potential systemic manifestations make diagnosis and therapeutic planning a complex challenge that requires a comprehensive and collaborative evaluation by a specialized medical team.

DIAGNOSIS

The diagnostic process of meningioma, a neoplastic entity derived from meningeal cells, is characterized as a comprehensive undertaking that requires the careful and meticulous application of multiple clinical, radiological, histopathological and genetic tools. Given the diversity of clinical presentations and the complexity of its biological behavior, the accurate diagnosis of meningioma demands a systemic and collaborative approach by specialized medical

professionals.Clinical evaluation constitutes the first pillar in the diagnostic pathway, in which neurological symptoms and systemic manifestations are thoroughly investigated and correlated with the patient's clinical history. Thorough anamnesis can provide crucial indicators about the duration, evolution and specific characteristics of the symptomatology, thus guiding the subsequent diagnostic exploration.

Neuroimaging modalities, led by magnetic resonance imaging (MRI) with gadolinium and non gadolinium contrasts, play a major role in the visualization and delineation of the radiological features of meningioma. The enhancement patterns, the degree of invasion into adjacent tissues and the anatomical location are essential criteria for the classification and follow-up of the neoplasm. In addition, advanced sequences such as diffusion weighting and MR spectroscopy provide valuable information about tumor viability and underlying molecular features.

Histopathologic confirmation is the gold standard in the diagnosis of meningiomas. Biopsy, which can be performed by open or image-guided procedures, allows detailed microscopic evaluation of cell morphology, growth patterns and the presence of atypical features. The intrinsic histologic variability of meningioma, encompassing grades from benign to anaplastic, reinforces the importance of expert interpretation and the application of consensus diagnostic criteria.

The application of genetic and molecular techniques has emerged as an increasingly relevant component in the diagnosis of meningioma. The detection of recurrent somatic mutations in genes such as NF2, SMARCB1 and POLR2A provides additional information on the underlying biology and can guide therapeutic strategy. Genomic sequencing and the identification of specific epigenetic profiles are paving the way towards more accurate characterization and risk stratification of meningiomas.

The diagnosis of meningioma is a multidimensional process involving the integration of clinical, radiological, histopathological and genetic data. A rigorous, multimodal approach is essential to achieve an accurate diagnosis and enable optimal therapeutic planning. Collaboration between medical specialists and leveraging state-of-the-art technologies are imperative to solve the diagnostic challenges inherent in this complex intracranial neoplasm.

TREATMENT

The therapeutic approach to meningioma, an intracranial neoplasm originating in the meninges, is a complex clinical challenge that demands a comprehensive and adaptive strategy, taking advantage of a variety of medical, surgical and radiotherapeutic modalities. The variable nature of this entity, ranging from tumors with indolent behavior to aggressive anaplastic variants, requires an individualized approach supported by a multidisciplinary team of healthcare professionals.

The therapeutic decision in the setting of meningioma is supported by careful consideration of multiple factors, including tumor location and size, histologic morphology, presence of atypical features, age and general health status of the patient, as well as specific therapeutic goals. In many cases, vigilant observation may be a reasonable option for asymptomatic or slow-growing meningiomas, especially in patients with significant comorbidities that limit invasive intervention.

Surgery represents a fundamental pillar in the therapeutic spectrum of meningioma, the main objective being complete resection of the tumor when technically feasible, preserving the surrounding brain structures as much as possible. Surgical technique can range from conventional microscopic resection to more advanced approaches such as neuronavigation-assisted surgery and fluorescence-guided resection. Intraoperative decision making informed by up-to-date imaging and preservation of neurological functions are crucial priorities in performing successful interventions.

In cases of recurrent, refractory or surgically high-risk meningiomas, radiotherapy emerges as a therapeutic alternative of considerable value. Radiotherapy options range from conventional radiotherapy to proton therapy and stereotactic radiosurgery, all of which are aimed at reducing tumor size and restricting progression. The choice of radiotherapeutic modality is based on tumor location and characteristics, tolerance of surrounding normal tissue, and individual patient preferences.Pharmacological advances are beginning to have an impact on the treatment of meningioma, especially in relapsed or refractory tumors. Angiogenesis inhibitors, such as bevacizumab, have shown some efficacy in controlling aggressive and recurrent tumors, although the benefits may be temporary and must be weighed against the potential risks. Research into therapies targeting specific genetic mutations, such as mutations in the NF2 gene, is ongoing and could revolutionize meningioma management in the future.

In conclusion, the management of meningioma is intricate and dynamic, requiring careful and adaptive evaluation that takes into account the diversity of clinical presentations and the biologic heterogeneity of the disease. The multidisciplinary approach, involving neurosurgeons, radiation oncologists, neuroradiologists, and nuclear medicine specialists, is essential for informed decision making and optimization of patient outcomes. The therapeutic paradigm for meningioma is constantly evolving, driven by advances in molecular understanding and technological innovation, in pursuit of improving the quality of life and survival of affected patients.

CONCLUSIONS

Meningioma, as an intracranial neoplastic entity originating in the meningeal membranes, embodies a clinical and pathological entity of significant medical relevance. Its

complexity lies in its clinical, morphological and biological variability, which confers both a diagnostic and therapeutic challenge. Throughout this comprehensive exploration, it has become evident that the approach to meningioma must be multifaceted and adaptive, anchored in interdisciplinary collaboration and up-to-date scientific knowledge.

The epidemiology of meningioma reveals distinctive demographic patterns, such as its predilection for women and its incidence increasing with age, highlighting the importance of a differential approach to diagnosis and clinical management. The clinical spectrum of meningioma is broad and its manifestations range from subtle neurological symptoms to severe functional deficits, largely dictated by the anatomical location and the pressure exerted on adjacent brain structures.

The diagnosis of meningioma, driven by the synergy of clinical, radiological, histopathological and genetic tools, is essential for accurate and personalized therapeutic planning. Neuroimaging, in particular MRI with advanced sequences, stands out as a fundamental pillar in tumor evaluation, allowing radiological characterization and three-dimensional visualization of the lesion. Histopathological confirmation, often achieved through image-guided biopsies, establishes the basis for classification and risk stratification, thus guiding the therapeutic approach.

The management of meningioma is based on an individualized approach that evaluates factors such as age, general health, tumor location and histologic morphology. Surgery, which can range from microscopic resection to more advanced approaches, remains an essential component of treatment, although radiotherapy emerges as a valuable alternative for recurrent or inoperable cases. Research into pharmacological and gene mutation-targeted therapies promises a more promising and personalized therapeutic horizon in the future

Ultimately, meningioma is a clinical challenge that evokes the need for a holistic and evolving approach. Collaboration between medical specialties, adoption of cutting-edge technologies, and the continued pursuit of a deeper understanding of the underlying biology are essential to improve early diagnosis, optimal management, and ultimately the prognosis and quality of life of patients affected by this intricate disease entity.

REFERENCES

I. Santamaría A, Martínez R, Astigarra I, Etxebarría J, Sánchez M. Ophthalmologic manifestations in pediatric brain tumors: 58 cases. Arch Soc Esp Oftalmol. 2008; 83:471-8.

II. De Luca S, Aguado AS, De Michelis V, Tisser L, Iribarren G, Eyheremendy E. Orbitocranial pathology of ophthalmologic presentation. Rev. argent. radiol. [Internet]. 2012 Jun;76(2):113-121.

III. Riordan-Eva P, Cunningham E. Vaughan and Asbury: general ophthalmology. 18th ed. Mc.Graw-Hill; 2012. p.p. 533.

IV. Sánchez Méndez F. The optic nerve and vision disorders. Med Integr. 2001;38:390-7.

V. Muñoz Negrete FJ, Rebolleda G. Automated perimetry and neuro-ophthalmology. Correlación topográfica / Automated perimetry and neuro-ophthalmology. Topographic correlation. Arch Soc Esp Oftalmol. 2002;77(8):413-28.

VI. Alegría-Loyola MA. Tumors of the central nervous system. Rev Med Inst Mex Seguro Soc. 2017;55(3):330-40.

VII. Leyva I, Guerrero G, Hernández J. Meningiomas: appearance by tomography and magnetic resonance imaging. Most frequent locations. Annals of Radiology Mexico. 2013;1:36-44.

VIII. Gelabert M, Serramito R. Intracranial meningiomas: II. Diagnosis and treatment. Rev Neurol. 2011;53:226-32.

IX. López Flores G, Samblas García J, Futiérrez-Díaz JA, Bustos P de Salcedo JC, Sallabanda Díaz K. Natural history and classifications of cranial base meningiomas. Rev Mex Neurosci. 2011;12(1):38-49.

X. Casas I. Meningiomas in neuro-oncology. 2016. Neurol Arg. 2016;8(3):210-26.

XI. Cammarata-Scalisi F, Stock F, Zambrano E, Milano M, Arenas de Sotolongo A, Petrosino P. Meningiomas in pediatric age. Presentation of two cases. Pediatr. (Asuncion). 2010;37(3):199-203.

XII. Goldbrunner R, Minniti G, Preusser M, Jenkinson MD, Sallabanda K, Houdart E, von Deimling A, Starvinou P, Lefranc F, Lund-Johansen M, Moyal EC, Brandsma D, Henriksson R, Soffietti R, Weller M. EANO guidelines for the diagnosis and treatment of meningiomas. Lancet Oncol. 2016 Sep;17(9):e383-91.

XIII. Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015 Jan;122(1):4-23.

XIV. Mawrin C, Chung C, Preusser M. Biology and Clinical Management Challenges in Meningioma. American Society of Clinical Oncology. ASCO educational book. asco. org/edbookMD. 2015:e106-e115.

XV. Rockhill J, Mrugala M, Chamberlain MC. Intracranial meningiomas: an overview of diagnosis and treatment. Neurosurg Focus. 23;2007(4);E1:1-7.